Caricamento...
Risk Factors for and Pre-medications to Prevent Cetuximab-Induced Infusion Reactions in Patients with Squamous Cell Carcinoma of the Head and Neck
OBJECTIVES: Cetuximab, a chimeric monoclonal antibody, is the only targeted therapy approved for squamous cell carcinoma of the head and neck (SCCHN). Infusion reactions (IRs) occur in 6–18% of patients pre-medicated with diphenhydramine. Evidence for clinical risk factors for IRs is limited and the...
Salvato in:
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4130782/ https://ncbi.nlm.nih.gov/pubmed/25037161 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2014.06.017 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|